Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S; I-SPY 2 Trial Consortium; Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. Yau C, et al. Among authors: van seijen m. Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11. Lancet Oncol. 2022. PMID: 34902335 Free PMC article.
Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
Steenbruggen TG, van Seijen M, Janssen LM, van Ramshorst MS, van Werkhoven E, Vrancken Peeters MTDF, Wesseling J, Lips EH, Sonke GS. Steenbruggen TG, et al. Among authors: van seijen m, van werkhoven e, van ramshorst ms. Clin Cancer Res. 2019 Aug 15;25(16):4985-4992. doi: 10.1158/1078-0432.CCR-19-0560. Epub 2019 May 10. Clin Cancer Res. 2019. PMID: 31076546
Enrichment of high-grade tumors in breast cancer gene expression studies.
van Seijen M, Mooyaart AL, Mulder L, Hoogstraat M, Drukker CA, Loo CE, Pouw B, Sonke GS, Wesseling J, Lips EH. van Seijen M, et al. Breast Cancer Res Treat. 2018 Apr;168(2):327-335. doi: 10.1007/s10549-017-4622-9. Epub 2017 Dec 18. Breast Cancer Res Treat. 2018. PMID: 29256013 Free PMC article.
Variability in grading of ductal carcinoma in situ among an international group of pathologists.
van Seijen M, Jóźwiak K, Pinder SE, Hall A, Krishnamurthy S, Thomas JS, Collins LC, Bijron J, Bart J, Cohen D, Ng W, Bouybayoune I, Stobart H, Hudecek J, Schaapveld M, Thompson A, Lips EH, Wesseling J; Grand Challenge PRECISION consortium.. van Seijen M, et al. J Pathol Clin Res. 2021 May;7(3):233-242. doi: 10.1002/cjp2.201. Epub 2021 Feb 23. J Pathol Clin Res. 2021. PMID: 33620141 Free PMC article.
Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.
Hoogstraat M, Lips EH, Mayayo-Peralta I, Mulder L, Kristel P, van der Heijden I, Annunziato S, van Seijen M, Nederlof PM, Sonke GS, Zwart W, Wesseling J, Wessels LFA. Hoogstraat M, et al. Among authors: van seijen m. NPJ Breast Cancer. 2022 May 6;8(1):60. doi: 10.1038/s41523-022-00428-8. NPJ Breast Cancer. 2022. PMID: 35523804 Free PMC article.
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.
El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S; International Immuno-Oncology Biomarker Working Group. El Bairi K, et al. NPJ Breast Cancer. 2021 Dec 1;7(1):150. doi: 10.1038/s41523-021-00346-1. NPJ Breast Cancer. 2021. PMID: 34853355 Free PMC article. Review.
Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast.
van Seijen M, Lips EH, Fu L, Giardiello D, van Duijnhoven F, de Munck L, Elshof LE, Thompson A, Sawyer E, Ryser MD, Hwang ES, Schmidt MK, Elkhuizen PHM; Grand Challenge PRECISION Consortium; Wesseling J, Schaapveld M. van Seijen M, et al. Br J Cancer. 2021 Nov;125(10):1443-1449. doi: 10.1038/s41416-021-01496-6. Epub 2021 Aug 18. Br J Cancer. 2021. PMID: 34408284 Free PMC article.
Ductal carcinoma in situ: to treat or not to treat, that is the question.
van Seijen M, Lips EH, Thompson AM, Nik-Zainal S, Futreal A, Hwang ES, Verschuur E, Lane J, Jonkers J, Rea DW, Wesseling J; PRECISION team. van Seijen M, et al. Br J Cancer. 2019 Aug;121(4):285-292. doi: 10.1038/s41416-019-0478-6. Epub 2019 Jul 9. Br J Cancer. 2019. PMID: 31285590 Free PMC article. Review.
[No title available]
[No authors listed] [No authors listed] PMID: 33574291
[No title available]
[No authors listed] [No authors listed] PMID: 33574288
20 results